Discovery of HIV-1 Integrase Inhibitors - Sanchez, Tino
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Highly active antiretroviral therapy (HAART) is the current treatment regimen for HIV/AIDS, a disease that has claimed millions worldwide. HAART is a cocktail that inhibits different stages of the viral life cycle targeting protease, reverse transcriptase, and often includes anti-fusion inhibitor enfurvitide. The addition of HIV-1 integrase (IN) inhibitor raltegravir to HAART reveals a decrease of the virus to near undetectable levels in treatment-experienced patients. Although these successes are encouraging for antiviral therapy, specific mutations resistant to raltegravir have also…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Highly active antiretroviral therapy (HAART) is the current treatment regimen for HIV/AIDS, a disease that has claimed millions worldwide. HAART is a cocktail that inhibits different stages of the viral life cycle targeting protease, reverse transcriptase, and often includes anti-fusion inhibitor enfurvitide. The addition of HIV-1 integrase (IN) inhibitor raltegravir to HAART reveals a decrease of the virus to near undetectable levels in treatment-experienced patients. Although these successes are encouraging for antiviral therapy, specific mutations resistant to raltegravir have also appeared. Drug resistant mutations is the inevitable signature of HIV with a merry-go-round history of antiviral drug development and viral evolution, highlighting the need to identify new leads for IN inhibition. Absent of a cellular
Autorenporträt
University of California at Davis, B.S., 1998 - 2002, Chemistry; University of Southern California, M.S., 2005 - 2007, Pharmaceutical Sciences; University of Sourthern California, Ph.D. Candidate, 2007 - 2011, Pharmacology and Pharmaceutical Sciences